Clinical trials: psoriasis
Atopic Dermatitis, Dermatology
A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions
The primary goal of the study is to collect standardized patient and clinician reported outcome measures for patients diagnosed with a range of dermatological conditions in an academic clinical practice setting.
- Conditions
- Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata
- Trial name
- ClinPRO-DERM (NCT05084417)
- Testing
- N/A This is an observational study
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- OM1, Inc.
Arthritis, Rheumatoid, Spondylitis, Ankylosing
C.O.R.P.U.S.: Observational Cohort of Adult and Child Inflammatory Arthritis in France
C.O.R.P.U.S. is the first French observatory of care practices in active inflammatory rheumatism of children and adults: rheumatoid arthritis, spondylarthropathy, and idiopathic juvenile arthritis, established under the auspices…
- Conditions
- Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Arthitis, Juvenile Idiopathic
- Trial name
- NCT02886689
- Testing
- TNF-alpha antagonist and other biotherapy
- Where
- France
- Volunteers
- 5,400 people
- Sponsor
- Central Hospital, Nancy, France
Psoriasis
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
- Trial name
- N/Z (NCT07489885)
- Testing
- D-2570 Tablet
- Where
- 20 sites in United States
- Volunteers
- 75 people
- Sponsor
- InventisBio Co., Ltd
Palmoplantar Pustulosis
A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis
- Trial name
- NCT03988335
- Testing
- RIST4721
- Where
- 17 sites in Canada, Germany
- Volunteers
- 35 people
- Sponsor
- Aristea Therapeutics, Inc.
Psoriasis Vulgaris
An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris
The purpose of this study is to evaluate the antipsoriatic effect of 5 different combinations of calcipotriol plus betamethasone dipropionate in Daivobet® gel vehicle in compared to Daivobet® gel in order to explore/find other…
- Trial name
- NCT01837576
- Testing
- Calcipotriol plus BDP gel in different doses
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Bioavailability of ASP015K, Pharmacokinetics of ASP015K
A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K
The purpose of this study is to determine the relative bioavailability and pharmacokinetic profiles from three strengths of a new tablet formulation of ASP015K and to evaluate the safety and tolerability after a single dose of…
- Conditions
- Bioavailability of ASP015K, Pharmacokinetics of ASP015K, Healthy Subjects
- Trial name
- NCT01486017
- Testing
- ASP015K
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Psoriasis (PsO), Psoriatic Arthritis (PsA)
A Clinical Trial of Antiplatelets in Psoriasis
The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more…
- Trial name
- NCT07744191
- Testing
- Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Psoriasis, Plaque-type Psoriasis
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
This study is designed to evaluate the proportion of patients achieving reversal of chronic plaque psoriasis at week 4 and 12 following multiple doses of secukinumab administered subcutaneously (sc) compared to placebo.
- Trial name
- NCT01537432
- Testing
- secukinumab
- Where
- 12 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
PET/CT in Psoriatic Arthritis
When patients with psoriasis develop joint pain, it is often hard to decide whether or not the pain is due to psoriatic arthritis (PsA).
- Trial name
- NCT01654198
- Testing
- FDG-PET/CT scan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Pennsylvania
Psoriasis
Efficacy of Two Algae Formulations on Lipid Metabolism, Inflammation and Oxidative Stress Status in Individuals With Psoriasis
Our overall goal is to evaluate the safety and efficacy of consumption of two algae formulations compared to a placebo on: degree of severity of skin lesions, plasma lipid levels, as well as other health-related markers, in…
- Trial name
- PCA (NCT01045395)
- Testing
- Corn starch, Unique Marine Algae Concentrate (UMAC), Golden brown algae
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Chronic Plaque-type Psoriasis
A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis
This will be a multicenter, double-blind, double-dummy, placebo controlled, randomized study to evaluate efficacy and safety of AUR101 (RORgamma inhibitor) in patients with moderate-to-severe psoriasis.
- Trial name
- INDUS-2 (NCT04207801)
- Testing
- AUR101
- Where
- 9 sites in India
- Volunteers
- 90 people
- Sponsor
- Aurigene Discovery Technologies Limited
Psoriasis
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to select doses for further clinical trials.
- Trial name
- NCT02054481
- Testing
- BI 655066, Ustekinumab
- Where
- 32 sites in United States, Canada and 5 more
- Volunteers
- 166 people
- Sponsor
- Boehringer Ingelheim
Moderate to Severe Plaque Psoriasis
Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.
Phase 1, drug-drug interaction study to evaluate the effects of Briakinumab on hte pharmacokinetics of single doses of CYP substrate in subjects with moderate to severe psoriasis.
- Trial name
- NCT01260844
- Testing
- briakinumab
- Volunteers
- 12 people
- Sponsor
- Abbott
Plaque Psoriasis
Study of CRx-191 to Assess Activity in Plaque Psoriasis
CRx-191 is a proprietary synergistic combination drug candidate being evaluated by CombinatoRx for topical psoriasis therapy. CRx-191 was identified via a proprietary screening assay for novel drug combinations demonstrating…
- Trial name
- NCT00557739
- Testing
- mometasone furoate, nortriptyline HCl
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Zalicus
Psoriasis
Study of a New Dressing for Use With Topical Medications
The purpose of this study is to determine if a new dressing designed to be used with topical medications will enhance the effects of these topical medications.
- Trial name
- NCT00234728
- Testing
- Occlusive dressing
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Teikoku Pharma USA, Inc.
Chronic Plaque Psoriasis
A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis
This is a phase 2, randomized, placebo-controlled, 2-period study to evaluate the safety, tolerability, and efficacy of belumosudil in adult subjects with moderate to severe chronic plaque psoriasis who are candidates for…
- Trial name
- NCT02852967
- Testing
- Belumosudil
- Where
- 14 sites in United States
- Volunteers
- 110 people
- Sponsor
- Kadmon Corporation, LLC
Psoriasis
The Maintenance Effect of Enstilar Foam in Combination With Otezla
This is a single-center, open-label study. Approximately 30 qualified subjects will be enrolled in a study lasting 20 weeks which investigates the effect of Enstilar used in combination with Otezla to treat psoriasis.
- Trial name
- NCT04555707
- Testing
- Apremilast 30mg, calcipotriene and betamethasone dipropionate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Derm Research, PLLC
Psoriasis, Metabolic Syndrome
Clinical Study of PET/CT and Association With Metabolic Syndrome/Depressive Symptoms in Psoriasis
Psoriasis is associated with increases in markers of inflammation in the skin and blood and increasingly is thought to be a systemic inflammatory disease and risk factor for incident diabetes mellitus, myocardial infarction…
- Conditions
- Psoriasis, Metabolic Syndrome, Depression
- Trial name
- NCT01661127
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Pusan National University Hospital
Psoriasis
A Registry of Patients With Moderate to Severe Plaque Psoriasis
The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis.
- Trial name
- PURE (NCT02786186)
- Testing
- Secikinumab
- Where
- 13 sites in Canada
- Volunteers
- 2,376 people
- Sponsor
- Novartis Pharmaceuticals
HIV Infections, Psoriasis
A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients
To evaluate the feasibility of Retrovir (AZT) in the treatment of psoriasis in HIV antibody positive patients. Retrovir has been shown to be effective in the treatment of AIDS.
- Trial name
- NCT00002286
- Testing
- Zidovudine
- Where
- United States
- Sponsor
- Glaxo Wellcome
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.